[go: up one dir, main page]

WO2018046737A1 - Polythérapie pour la mucopolysaccharidose de type vi (syndrome de maroteaux-lamy) - Google Patents

Polythérapie pour la mucopolysaccharidose de type vi (syndrome de maroteaux-lamy) Download PDF

Info

Publication number
WO2018046737A1
WO2018046737A1 PCT/EP2017/072779 EP2017072779W WO2018046737A1 WO 2018046737 A1 WO2018046737 A1 WO 2018046737A1 EP 2017072779 W EP2017072779 W EP 2017072779W WO 2018046737 A1 WO2018046737 A1 WO 2018046737A1
Authority
WO
WIPO (PCT)
Prior art keywords
ert
aav
value
vector
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/072779
Other languages
English (en)
Inventor
Alberto Auricchio
Marialuisa ALLIEGRO
Rita FERLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Telethon
Original Assignee
Fondazione Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Telethon filed Critical Fondazione Telethon
Priority to EP17768071.7A priority Critical patent/EP3509628A1/fr
Publication of WO2018046737A1 publication Critical patent/WO2018046737A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates to a method for the treatment of MPS VI comprising administering an arylsulfatase B by gene therapy to a subject in need thereof, wherein said subject is also administered with an arylsulfatase B enzyme replacement therapy (ERT) less frequently than once a week.
  • ERT arylsulfatase B enzyme replacement therapy
  • Lysosomal storage diseases include more than 40 distinct inherited metabolic diseases as autosomal or X-linked recessive. The majority of LSDs are caused by deficient activity of specific lysosomal hydrolases and the progressive accumulation of their substrate(s), which ultimately leads to multisystem cellular and organ dysfunction 1 .
  • mucolopolysaccharidosis type 6 is a lysosomal storage disease in which the affected patients lack the enzyme Arylsulfatase B (N-acetylgalactosamine-4-sulfatase, chondroitinsulfatase, chondroitinase, acetylgalactosamine 4-sulfatase, N-acetylgalactosamine 4-sulfate sulfohydrolase, ARSB, ASB), hereinafter ARSB.
  • Arylsulfatase B N-acetylgalactosamine-4-sulfatase, chondroitinsulfatase, chondroitinase, acetylgalactosamine 4-sulfatase, N-acetylgalactosamine 4-sulfate sulfohydrolase, ARSB, ASB), hereinafter ARSB.
  • the enzyme hydrolyses sulfates in the body, by metabolizing the sulfate moiety of glycosaminoglycans (GAGs), which are heterogeneous large sugar molecules in the body 70 .
  • GAGs glycosaminoglycans
  • ARSB targets two GAGs in particular: dermatan sulfate and chondroitin sulfate.
  • Lysosomal accumulation of the glycosaminoglycan dermatan sulfate is accompanied by urinary excretion of elevated amounts of the same 28 .
  • the accumulation of GAGs causes a progressive disorder with multiple organ and tissue involvement in which the infant appears normal at birth, but usually dies before puberty.
  • the diagnosis of MPS VI is usually made at 6-24 months of age when children show progressive deceleration of growth, enlarged liver and spleen, skeletal deformities, coarse facial features, upper airway obstruction, and joint deformities. Progressive clouding of the cornea, communicating hydrocephalus, or heart disease may develop in MPS VI children. Death usually results from respiratory infection or cardiac disease.
  • MPS VI is not typically associated with progressive impairment of mental status, although physical limitations may impact learning and development.
  • ERT intravenous infusions Despite its ability to ameliorate patient outcomes and slow disease progression, the requirement of weekly or bi-weekly (i.e. twice a week) ERT intravenous infusions, which is due to the short plasma half-life of recombinant enzymes 5 ' 6 , carries a risk of immune-mediated allergic reactions 7 and often requires a central venous access, resulting in a low quality of life for the patients.
  • ERTs are extremely expensive and this represents a barrier for their widespread use in less developed countries 4 ' 8 . Therefore, there is high need to develop new therapeutic strategies with comparable or better efficacy than ERT, but without the inconvenience of multiple infusions associated to ERT.
  • Gene therapy is emerging as a successful strategy for the treatment of inherited diseases, including LSDs 9 ⁇ u .
  • Vectors based on adeno-associated viruses (AAVs) are the most frequently used for in vivo applications of gene therapy, because of their safety profile, wide tropism and ability to provide long-term transgene expression 12 .
  • AAV-mediated gene therapy has been tested successfully in both small and large animal models of LSDs, including Pompe disease, Fabry disease, and mucopolysaccharidoses (MPS) 13 ⁇ 24 .
  • AAV vectors serotype 8 (AAV2/8) are being explored to convert the liver into a factory organ for the systemic release of therapeutic proteins.
  • the inventors used a similar approach in animal models of MPS VI and demonstrated that a single systemic administration of AAV2/8 encoding ARSB is able to convert the liver into a source of systemic ARSB. 13 ⁇ 16 ' 19 .
  • gene therapy may have some limitations.
  • liver enzymes were increased in subjects receiving a dose of vector of 2x10 12 gc/kg, likely due to cell-mediated immune responses to AAV8, which lead to the elimination of transduced hepatocytes.
  • This increase in liver transaminases was successfully controlled with a short course of glucocorticoids 26 ' 21 , however either close monitoring of liver enzymes or prophylactic oral corticosteroids are required to avoid loss of transgene expression.
  • HCC hepatocellular carcinoma
  • the present invention relates to a combination therapy for MPS VI comprising gene therapy and enzyme replacement therapy (ERT), wherein the ERT is administered less frequently than once a week, less frequently than once every two weeks, less frequently than once every 3 weeks, preferably less frequently than once every 4 weeks, preferably less frequently than once every 8 weeks, preferably less frequently than once every 12 week.
  • ERT enzyme replacement therapy
  • the present invention is based on the surprising finding that a greater reduction of urinary GAGs, considered a sensitive and reliable biomarker of lysosomal storage clearance and therapeutic efficacy, was observed in mice receiving the combined therapy (gene therapy + ERT) when compared to single ERT. Indeed, urinary GAGs were reduced by 59% compared to affected (AF) controls in mice treated with both 2x lO n gc/kg of AAV and ERT than in mice treated with either monthly ERT (82% of AF) or 2x lO n gc/kg of AAV (73% of AF).
  • the present invention provides a combination comprising:
  • a vector comprising a nucleic acid encoding an arylsulfatase B and
  • ERT for use in the treatment of MPS VI, wherein the ERT is administered less frequently than once a week.
  • the present invention also provides a method for the treatment of MPS VI comprising:
  • ERT arylsulfatase B enzyme replacement therapy
  • ERT is administered less frequently than once a week.
  • the nucleic acid encodes a wild-type arylsulfatase B.
  • wild-type arylsulfatase B comprises SEQ ID No. 2 or SEQ ID No. 4.
  • nucleic acid comprises SEQ ID No. 1.
  • nucleic acid is operably linked to a liver-specific promoter.
  • the liver-specific promoter is selected from the group consisting of: thyroxine- binding globulin (TBG) promoter, alfa-l-antitripsin promoter, albumin promoter.
  • TBG thyroxine- binding globulin
  • alfa-l-antitripsin promoter alfa-l-antitripsin promoter
  • albumin promoter alfa-l-antitripsin promoter
  • the thyroxine-binding globulin (TBG) promoter comprises SEQ ID No. 11
  • the alfa- l-antitripsin promoter comprises SEQ ID No. 12
  • the albumin promoter comprises SEQ ID No. 13.
  • the vector comprises SEQ ID No. 3.
  • the vector is selected from the group consisting of: an adenoviral vector, lentiviral vector, retroviral vector, adeno associated vector (AAV) or naked plasmid DNA vector.
  • AAV adeno associated vector
  • the vector is an adeno-associated viral (AAV) vector.
  • AAV adeno-associated viral
  • the AAV vector is of serotype 8.
  • the vector comprises SEQ ID No. 8.
  • the dosage of the vector is of from lxlO 9 to 2xl0 16 gc/kg, preferably of from 2xlO n gc/kg to 2xl0 12 gc/kg, more preferably is about 6xlO n gc/kg.
  • the vector is administered intravenously.
  • the arylsulfatase B in the ERT comprises SEQ ID No. 2 or SEQ ID No. 4.
  • the arylsulfatase B in the ERT is a recombinant arylsulfatase B.
  • the arylsulfatase B in the ERT is administered at a dose range of 0.001 mg/kg to 5 mg/kg, preferably at a dose range of 0.5mg/kg to 4 mg/kg, more preferably at a dose of 1 mg/kg.
  • the arylsulfatase B in the ERT is administered intravenously.
  • the arylsulfatase B enzyme replacement therapy is administered less frequently than once every 2 weeks, preferably less frequently than once every 3 weeks, preferably less frequently than once every 4 weeks, preferably less frequently than once every 8 weeks, preferably less frequently than once every 12 weeks.
  • the vector is administered at a dose ranging from 2x10 11 gc/kg to 2x10 12 gc/kg and the arylsulfatase B enzyme replacement therapy (ERT) is administered at a dose of 1 mg/kg and less frequently than once a week, preferably once a month.
  • ERT arylsulfatase B enzyme replacement therapy
  • the vector and the arylsulfatase B enzyme replacement therapy are administered at different times.
  • the vector is administered prior to the initiation of the arylsulfatase B enzyme replacement therapy.
  • the vector may be administered few hours (1 to 12 hours) or few days (1 to 5 days) or few months (1 to 6 months) prior to the initiation of the arylsulfatase B enzyme replacement therapy.
  • the vector is administered simultaneously with initiation of the arylsulfatase B enzyme replacement therapy.
  • the vector is administered only once.
  • the vector is administered after the initiation of the arylsulfatase B enzyme replacement therapy.
  • the vector may be administered few hours (1 to 12 hours) or few days (1 to 5 days) or few months (1 to 6 months) after the initiation of the arylsulfatase B enzyme replacement therapy.
  • Enzyme replacement therapy involves the systemic administration of natural or recombinantly-derived proteins and/or enzymes to a subject.
  • Approved therapies are typically administered to subjects intravenously and are generally effective in treating the somatic symptoms of the underlying enzyme deficiency.
  • ERT is a treatment replacing an enzyme in cells, e.g. patients cells, in whom that particular enzyme is deficient or absent.
  • An arylsulfatase B in the precursor form, or a biologically active fragment, variant or analog thereof catalyzes the cleavage of the sulfate ester from terminal N acetylgalactosamine 4-sulfate residues of glycosaminoglycans (GAG), chondroitin 4-sulfate and dermatan sulfate.
  • GAG glycosaminoglycans
  • Wild-type is a term referring to the natural form, including sequence, of a polynucleotide, polypeptide or protein in a species.
  • a wild-type form is distinguished from a mutant form of a polynucleotide, polypeptide or protein arising from genetic mutation(s).
  • recombinant is used herein to refer to recombinant DNA molecules, eg DNA molecules formed by laboratory methods of genetic recombination (such as molecular cloning) to bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome.
  • Recombinant is also used to refer to peptides, proteins and entire organisms made using said techniques well known and can be found in the published literature including, for example, in Sambrook et al, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).
  • variant means a form having a certain percent sequence identity to the native/wild- type forms.
  • Variants “functional” or “biologically active” means that the variant protein is capable of metabolizing glycosaminoglycan dermatan sulfate in vivo.
  • a first polypeptide that is an "analog” or “variant” or “derivative” of a second polypeptide is a polypeptide having at least about 50%, 60%, 70%>, 80%>, 85%, 90%, 95%), 96%), 97%o, 98%o or 99% sequence homology, but less than 100% sequence homology, with the second polypeptide.
  • Such analogs, variants or derivatives may be comprised of non- naturally occurring amino acid residues, including without limitation, homoarginine, ornithine, penicillamine, and norvaline, as well as naturally occurring amino acid residues.
  • nucleic acid and percent “identity” in the context of two or more polynucleotide or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. In a preferred embodiment, percent identity is determined over the full length of the two nucleic acid or amino acid sequences being compared.
  • substantially homologous in the context of two nucleic acid or polypeptide sequences, generally refers to two or more sequences or subsequences that have at least 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% nucleotide or amino acid sequence identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.
  • the substantial homology or identity exists over regions of the sequences that are at least about 25, 50, 100 or 150 nucleic acid or amino acid residues in length.
  • the sequences are substantially homologous or identical over the entire length of either or both comparison sequences.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are inputted into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
  • Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math., 2: 482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol., 48: 443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection.
  • PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol, 35: 351-360 (1987) and is similar to the method described by Higgins & Sharp, CABIOS, 5: 151-153 (1989).
  • Another algorithm useful for generating multiple alignments of sequences is Clustal W (Thompson et al, Nucleic Acids Research, 22: 4673-4680 (1994)).
  • An example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm (Altschul et al, J. Mol. Biol., 215: 403-410 (1990); Henikoff & Henikoff, Proc. Natl. Acad.
  • an arylsulfatase B or a precursor form thereof, or a variant, a biological active fragment thereof, or an analog thereof has specific activity in the range of 20-90 units, and more preferably greater than about 50 units per mg protein.
  • the preferred specific activity of the ARSB according to the present invention is about 20-90 Unit, and more preferably greater than 50 units per milligram protein.
  • the enzyme has a deglycosylated weight of about 55 to 56 kDa, most preferably about 55.7 kDa.
  • the enzyme has a glycosylated weight of about 63 to 68 kDa, most preferably about 64 to 66 kDa.
  • the present invention also includes biologically active fragments including truncated molecules, analogs and mutants of the naturally-occurring human ARSB.
  • parenteral or non-parenteral routes of administration including oral, transdermal, transmucosal, intrapulmonary (including aerosolized), intramuscular, subcutaneous, or intravenous that deliver equivalent dosages are contemplated.
  • Administration by bolus injection or infusion directly into the joints or CSF is also specifically contemplated, such as intrathecal, intracerebral, intraventricular, via lumbar puncture, or via the cistema magna.
  • intrathecal administration including pumps, reservoirs, shunts or implants.
  • the doses are delivered via intravenous infusions lasting 1, 2 or 4 hours, most preferably 4 hours, but may also be delivered by an intravenous bolus.
  • the ERT according to the present invention is administered intravenously over approximately a four-hour period. Also, preferably, it is administered by an intravenous catheter placed in the cephalic or other appropriate vein with an infusion of saline begun at about 30 cc/hr. Further, preferably it is diluted into about 250 cc of normal saline.
  • the ERT may be administered in a number of ways in addition to the preferred embodiments described above, such as parenteral, topical, intranasal, inhalation or oral administration.
  • the ERT is formulated in a pharmaceutical composition, together with a pharmaceutically-acceptable carrier which may be solid, semi-solid or liquid or an ingestable capsule.
  • a pharmaceutically-acceptable carrier which may be solid, semi-solid or liquid or an ingestable capsule.
  • pharmaceutical compositions include tablets, drops such as nasal drops, compositions for topical application such as ointments, jellies, creams and suspensions, aerosols for inhalation, nasal spray, liposomes.
  • the recombinant enzyme comprises between 0.05 and 99% or between 0.5 and 99% by weight of the composition, for example between 0.5 and 20% for compositions intended for injection and between 0.1 and 50% for compositions intended for oral administration.
  • a particularly preferred method of administering the recombinant enzyme is intravenously.
  • a particularly preferred composition comprises recombinant ARSB, normal saline, phosphate buffer to maintain the pH at about 5-7, and human albumin.
  • the composition may additionally include polyoxyethylenesorbitan, such as polysorbate 20 or 80 (Tween-20 or Tween-80) to improve the stability and prolong shelf life.
  • the composition may include any surfactant or non-ionic detergent known in the art, including but not limited to polyoxy ethylene sorbitan 40 or 60; polyoxyethylene fatty acid esters; polyoxyethylene sorbitan monoisostearates; poloxamers, such as poloxamer 188 or poloxamer 407; octoxynol-9 or octoxynol 40.
  • surfactant or non-ionic detergent known in the art, including but not limited to polyoxy ethylene sorbitan 40 or 60; polyoxyethylene fatty acid esters; polyoxyethylene sorbitan monoisostearates; poloxamers, such as poloxamer 188 or poloxamer 407; octoxynol-9 or octoxynol 40.
  • the ERT is formulated as 1 mg/mL ARSB in 150 mM NaCl, 10 mM NaPO.sub.4, pH 5.8, 0.005% polysorbate 80.
  • Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease.
  • Gene therapy comprises administering a vector comprising a nucleic acid encoding an arylsulfatase B.
  • nucleic acid comprises SEQ ID No. 1.
  • said vector is a vector selected from the group consisting of: adenoviral vectors, lentiviral vectors, retroviral vectors, adeno associated vectors (AAV) or naked plasmid DNA vectors.
  • said vector is an adeno-associated virus vector.
  • AAV adeno-associated virus vector.
  • an "AAV vector” refers to nucleic acids, either single- stranded or double- stranded, having an AAV 5' inverted terminal repeat (ITR) sequence and an AAV 3' ITR flanking a polynucleotide encoding ARSB operably linked to transcription regulatory elements that are heterologous to the AAV viral genome, i.e., one or more promoters and/or enhancers and, optionally, a polyadenylation sequence and/or one or more introns inserted between exons of the protein-coding sequence.
  • ITR inverted terminal repeat
  • a single-stranded AAV vector refers to nucleic acids that are present in the genome of an AAV virus particle, and can be either the sense strand or the anti-sense strand of the nucleic acid sequences disclosed herein. The size of such single- stranded nucleic acids is provided in bases.
  • a double-stranded AAV vector refers to nucleic acids that are present in the DNA of plasmids, e.g., pUC19, or genome of a double-stranded virus, e.g., baculovirus, used to express or transfer the AAV vector nucleic acids.
  • the size of such double-stranded nucleic acids in provided in base pairs (bp).
  • AAV vectors of the present invention comprise a nucleic acid sequence encoding a functional ARSB protein.
  • AAV virion or “AAV viral particle” or “AAV vector particle” refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. If the particle comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild- type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an "AAV vector particle” or simply an "AAV vector”. Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.
  • a heterologous polynucleotide i.e. a polynucleotide other than a wild- type AAV genome such as a transgene to be delivered to a mammalian cell
  • AAV “rep” and “cap” genes are genes encoding replication and capsid proteins, respectively.
  • AAV rep and cap genes have been found in all AAV serotypes examined to date, and are described herein and in the references cited. In wild-type AAV, the rep and cap genes are generally found adjacent to each other in the viral genome (i.e., they are “coupled” together as adjoining or overlapping transcriptional units), and they are generally conserved among AAV serotypes.
  • AAV rep and cap genes are also individually and collectively referred to as "AAV packaging genes".
  • the AAV cap genes in accordance with the present invention encode capsid proteins which are capable of packaging AAV vectors in the presence of rep and adeno helper function and are capable of binding target cellular receptors.
  • the AAV cap gene encodes a capsid protein having an amino acid sequence derived from a particular AAV serotype, for example the serotypes shown in Table 1.
  • the AAV sequences employed for the production of AAV can be derived from the genome of any AAV serotype.
  • the AAV serotypes have genomic sequences of significant homology at the amino acid and the nucleic acid levels, provide a similar set of genetic functions, produce virions which are essentially physically and functionally equivalent, and replicate and assemble by practically identical mechanisms.
  • genomic sequence of AAV serotypes and a discussion of the genomic similarities see, for example, GenBank Accession number U89790; GenBank Accession number J01901; GenBank Accession number AF043303; GenBank Accession number AF085716; Chiorini et al, J. Vir.
  • the genomic organization of all known AAV serotypes is very similar.
  • the genome of AAV is a linear, single-stranded DNA molecule that is less than about 5,000 nucleotides (nt) in length.
  • Inverted terminal repeats (ITRs) flank the unique coding nucleotide sequences for the non- structural replication (Rep) proteins and the structural (VP) proteins.
  • the VP proteins form the capsid.
  • the terminal 145 nt are self-complementary and are organized so that an energetically stable intramolecular duplex forming a T-shaped hairpin may be formed. These hairpin structures function as an origin for viral DNA replication, serving as primers for the cellular DNA polymerase complex.
  • the Rep genes encode the Rep proteins, Rep78, Rep68, Rep52, and Rep40.
  • Rep78 and Rep68 are transcribed from the p5 promoter
  • Rep 52 and Rep40 are transcribed from the pi 9 promoter.
  • the cap genes encode the VP proteins, VP1, VP2, and VP3.
  • the cap genes are transcribed from the p40 promoter.
  • the ITRs employed in the vectors of the present invention may correspond to the same serotype as the associated cap genes, or may differ. In a particularly preferred embodiment, the ITRs employed in the vectors of the present invention correspond to an AAV2 serotype and the cap genes correspond to an AAV8 serotype.
  • inverted terminal repeat refers to the art-recognized regions found at the 5' and 3' termini of the AAV genome which function in cis as origins of DNA replication and as packaging signals for the viral genome.
  • AAV ITRs together with the AAV rep coding region, provide for efficient excision and rescue from, and integration of a nucleotide sequence interposed between two flanking ITRs into a host cell genome. Sequences of certain AAV-associated ITRs are disclosed by Yan et al, J. Virol. 79(l):364-379 (2005) which is herein incorporated by reference in its entirety.
  • ITR sequences that find use herein may be full length, wild-type AAV ITRs or fragments thereof that retain functional capability, or may be sequence variants of full-length, wild-type AAV ITRs that are capable of functioning in cis as origins of replication.
  • AAV ITRs useful in the recombinant AAV vectors of the present invention may derive from any known AAV serotype and, in certain preferred embodiments, derive from the AAV2 or AAV8 serotype.
  • Viral vectors according to the invention may comprise a recombinant nucleic acid operatively linked to transcription regulatory elements.
  • Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro and the modified cells are administered to patients (ex vivo).
  • transcription regulatory element refers to nucleotide sequences of a gene involved in regulation of genetic transcription including a promoter, plus response elements, activator and enhancer sequences for binding of transcription factors to aid RNA polymerase binding and promote expression, and operator or silencer sequences to which repressor proteins bind to block RNA polymerase attachment and prevent expression.
  • promoter plus response elements, activator and enhancer sequences for binding of transcription factors to aid RNA polymerase binding and promote expression, and operator or silencer sequences to which repressor proteins bind to block RNA polymerase attachment and prevent expression.
  • liver specific transcription regulatory element refers to a regulatory element that modulates gene expression specifically in the liver tissue.
  • liver specific regulatory elements include, but are not limited to, the mouse thyretin promoter (mTTR), the endogenous human factor VIII promoter (F8), human alpha- 1 -antitrypsin promoter (hAAT) and active fragments thereof, human albumin minimal promoter, human thyroxine binding globulin (TBG) promoter, and mouse albumin promoter.
  • Enhancers derived from liver specific transcription factor binding sites are also contemplated, such as EBP, DBP, HNF1, HNF3, HNF4, HNF6, with Enhl .
  • Non-viral vector delivery systems include DNA or RNA plasmids, DNA MCs, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
  • “Pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, buffers, and the like, such as a phosphate buffered saline solution, 5% aqueous solution of dextrose, and emulsions (e.g., an oil/water or water/oil emulsion).
  • excipients include adjuvants, binders, fillers, diluents, disintegrants, emulsifying agents, wetting agents, lubricants, glidants, sweetening agents, flavoring agents, and coloring agents.
  • Suitable pharmaceutical carriers, excipients and diluents are described in Remington's Pharmaceutical Sciences, 19th Ed. (Mack Publishing Co., Easton, 1995).
  • Preferred pharmaceutical carriers depend upon the intended mode of administration of the active agent.
  • Typical modes of administration for protein therapeutics include enteral (e.g., oral) or parenteral (e.g., subcutaneous, intramuscular, intravenous or intraperitoneal injection; or topical, transdermal, or transmucosal administration).
  • a “pharmaceutically acceptable salt” is a salt that can be formulated into a compound for pharmaceutical use, including but not limited to metal salts (e.g., sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
  • metal salts e.g., sodium, potassium, magnesium, calcium, etc.
  • salts of ammonia or organic amines e.g., sodium, potassium, magnesium, calcium, etc.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or without interacting in a deleterious manner with any of the components of the composition in which it is contained or with any components present on or in the body of the individual.
  • the term "subject” encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the mammalian class: humans, non- human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish, and the like. The term does not denote a particular age or gender.
  • the term "effective amount” means a dosage sufficient to produce a desired result on a health condition, pathology, or disease of a subject or for a diagnostic purpose.
  • the desired result may comprise a subjective or objective improvement in the recipient of the dosage.
  • “Therapeutically effective amount” refers to that amount of an agent effective to produce the intended beneficial effect on health.
  • An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • Treatment refers to prophylactic treatment or therapeutic treatment. In certain embodiments, “treatment” refers to administration of a compound or composition to a subject for therapeutic or prophylactic purposes.
  • a “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs of the disease, for the purpose of decreasing the risk of developing pathology.
  • the compounds or compositions of the disclosure may be given as a prophylactic treatment to reduce the likelihood of developing a pathology or to minimize the severity of the pathology, if developed.
  • a “therapeutic” treatment is a treatment administered to a subject who exhibits signs or symptoms of pathology for the purpose of diminishing or eliminating those signs or symptoms.
  • the signs or symptoms may be biochemical, cellular, histological, functional or physical, subjective or objective.
  • the compounds of the disclosure may also be given as a therapeutic treatment.
  • Deficiency in ARSB activity can be observed, e.g., as activity levels of 50% or less, 25% or less, or 10% or less compared, to normal levels of ARSB activity and can manifest as a mucopolysaccharidosis, for example mucopolysaccharidosis VI (MPS VI) or Maroteaux-Lamy syndrome.
  • MPS VI mucopolysaccharidosis VI
  • Maroteaux-Lamy syndrome e.g., as activity levels of 50% or less, 25% or less, or 10% or less compared, to normal levels of ARSB activity and can manifest as a mucopolysaccharidosis, for example mucopolysaccharidosis VI (MPS VI) or Maroteaux-Lamy syndrome.
  • a therapy according to the invention displays therapeutically efficacy when it provides a beneficial effect in the human patient and preferably provides improvements in any one of the following: joint mobility, pain, or stiffness, either subjectively or objectively; exercise tolerance or endurance, for example, as measured by walking or climbing ability; pulmonary function, for example, as measured by FVC, FEV.sub.l or FET; cardiac function, for example, as measured by ventricular hypertrophy, valve obstruction, or valve regurgitation; visual acuity; or activities of daily living, for example, as measured by ability to stand up from sitting, pull clothes on or off, or pick up small objects.
  • therapeutic efficacy of treatment is displayed by reduction in urinary GAG excretions of at least 20%, at least 30%, at least 40%, at least 50%, at least 80%, at least 90 % compared to urinary GAG excretion prior to treatment.
  • a combination therapy is a therapeutic intervention in which more than one therapy is administered to the subject.
  • the precise dose and schedule of administration will depend on the stage and severity of the condition, and the individual characteristics of the patient being treated, as well as the most effective biological activity of treatment as will be appreciated by one of ordinary skill in the art. It is also contemplated that the treatment continues until satisfactory results are observed, which can be as soon as after 1 cycle although from about 3 to about 6 cycles or more cycles may be required such as in a maintenance schedule of administration.
  • the exact amount, frequency and period of administration of the ERT or gene therapy of the present invention will vary, of course, depending upon the sex, age and medical condition of the patient as well as the severity and type of the disease as determined by the attending clinician.
  • the schedule of treatment with the combination can foresee that the ERT is administered concomitantly, before and/or after the gene therapy identified above. Interval between ERT and gene therapy may vary from days to weeks.
  • Still further aspects include combining the therapy described herein with other therapies for synergistic or additive benefit.
  • ERT is administered at least once.
  • the combination produces a diminution in glycosaminoglycans (GAG) levels.
  • GAG glycosaminoglycans
  • the dosage of the vector for gene therapy is of from lxlO 9 to 2xl0 16 gc/kg, preferably of from 2xl0 10 gc/kg to 2xl0 14 gc/kg, preferably of from 2xlO n gc/kg to 2xl0 12 gc/kg, more preferably is about 6x10 11 gc/kg.
  • a preferred dose of enzyme is 1 mg/kg.
  • a preferred dose of vector is less than 2xl0 12 gc/kg, preferably about 6x10 11 gc/kg.
  • glycosaminoglycans levels in urine and tissues may be measured by any known method in the art for instance as described in 72 ' 73 and in the material and method section below.
  • FIG. 1 Reduction of urinary GAGs in mice receiving gene therapy and/or monthly ERT.
  • Urinary GAGs were measured monthly in treated MPS VI mice (gray bars), in normal (NR, white bars) and affected (AF, black bars) controls. Urinary GAG levels measured were averaged for all animals within the same group of treatment and for all time points and the resulting value is reported as a percentage (%) of age-matched AF controls, as indicated inside each bar. Results are represented as mean ⁇ SE.
  • FIG. 3 Reduction of urinary GAGs in mice receiving gene therapy and/or monthly ERT.
  • Urinary GAGs were measured in treated MPS VI mice (gray bars), in normal (NR, white bars) and in affected (AF, black bars) controls. Urinary GAG levels measured at each time point were averaged for all animals within the same group of treatment and the resulting value is reported as a percentage (%) of age-matched AF controls, as indicated above each bar. Results are represented as mean ⁇ SE.
  • FIG. 4 Alcian blue staining in the liver, kidney and spleen of mice receiving gene therapy and/or monthly ERT. Reduction of GAGs storage in the liver, kidney and spleen was also evaluated by Alcian blue staining of histological sections obtained from MPS VI mice receiving AAV and/or monthly ERT and from normal (NR) and affected (AF) mice. All MPS VI treated mice that were sacrificed between days 180 and 210 of age were included in the histological analysis. Representative images are shown. Scale bar is 40 ⁇ (magnification is 20X).
  • FIG. 5 Reduction of GAG storage in the heart valves and myocardium of mice receiving gene therapy and/or monthly ERT. Reduction of GAGs storage in the heart valves and myocardium was evaluated by Alcian blue staining of histological sections obtained from MPS VI mice receiving AAV.TBG.M&S5 (AAV) and/or monthly ERT (ERT) and from normal (NR) and affected (AF) controls. All MPS VI treated mice that were sacrificed between days 180 and 210 of age were included in the histological analysis. Representative images are shown. A scale bar is indicated inside the figure (magnification is 40X). Alcian blue staining was quantified as a measure of GAGs storage in heart valves and myocardium.
  • Alcian Blue was quantified using the Image J software by measuring RGB intensity on images of histological sections. Results are reported inside each representative image and in the relative histogram OF Fig. 8 and 9 as mean ⁇ SE.
  • Statistical comparisons were made using the one-way ANOVA and the Tukey post hoc test.
  • the p value vs. AF is: ** « 0.01. The exact p values obtained are indicated in the Material and Methods section.
  • Beta-glucuronidase (GUSB) activity was measured in liver (a) and kidney (b) of treated MPS VI mice (gray bars), and of normal (NR, white bars) and affected (AF, black bars) controls. GUSB activity was averaged for all animals within the same group of treatment and the resulting value is reported as mean ⁇ SE. The number of animals is 5 per each group. Statistical comparisons were made using the one-way ANOVA and the Tukey post hoc test. The p value vs AF is: * ⁇ 0.05 and ** « 0.01. The exact / ⁇ -values obtained are indicated in the Material and Methods section. Abbreviations: AAV, AA r 2, ⁇ 8.TBG. hARSB; ERT, monthly ERT.
  • FIG. 7 Map of vector used for gene therapy in the examples, according to a preferred embodiment of the invention.
  • Figure 8 Histogram representing results of Alcian blu quantification of figure 5 in heart valves.
  • Figure 9 Histogram representing results of Alcian blu quantification of figure 5 in myocardium
  • TSG Human thyroxine-binding globulin (TBG) promoter: nt 220-917 which AMBP enhancer (alpha-l-microglobulin/bikunin precursor) gene transcription regulatory region,: nt 220-426)
  • hARSB Coding sequence nt 1103-2704
  • Bovine Growth Hormone (BGH) polyA nt 2744-2951 SEQ ID No. 4 galsulfase
  • TSG Human thyroxine-binding globulin (TBG) promoter: nt 220-917 which AMBP enhancer (alpha-l-microglobulin/bikunin precursor) gene transcription regulatory region,: nt 220-426)
  • hARSB Coding sequence nt 1103-2704
  • Bovine Growth Hormone (BGH) polyA nt 2744-2951
  • TBG promoter nt 678-1154
  • MPS VI mice were maintained at the Cardarelli Hospital Animal House (Naples, Italy). Animals were raised in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines for the care and use of animals in research.
  • This mouse model carries a targeted disruption of the ARSB locus 64 and is made immune-tolerant to human ARSB by transgenic insertion of the C91S hARSB mutant, resulting in the production of inactive hARSB 65 .
  • Six out of 38 MPS VI mice from the same genetic background had the C91S hARSB transgene inserted into the ROSA26 locus 66 , while the remaining presented random integrations of this transgene 15 .
  • Genotype analysis was performed by polymerase chain reaction (PCR) on genomic DNA obtained from the tail, as previously described 15 . Plasmid and vector production
  • the plasmid pAA ⁇ 2A .T G-hARSB (see Figure 7) encoding the hARSB protein was generated, as described previously 19 .
  • the gene therapy AAV2/8.TBG.A ⁇ 4i?55 and the control AAV2/8.TBG.eG vectors were produced by the AAV Vector Core (Telethon Institute of Genetics and Medicine [TIGEM], Pozzuoli, Naples, Italy), as previously described 14 .
  • MPS VI mice were treated with gene therapy and/or ERT through intravenous retro-orbital injections, starting from p30 to avoid vector dilution due to hepatocyte proliferation 13 ' 56 ' 57 and were followed up to 6-7 months (180-210 post-natal days) of age.
  • MPS VI mice were treated with a single injection of the AA 2I% G.
  • hARSB vector at either 2xlO n or 6xlO n gc/kg and/or monthly injections of 1 mg/kg rhARSB protein (Naglazyme, BioMarin Europe, London, UK), appropriately diluted in phosphate buffered saline (PBS).
  • mice were sacrificed 5 or 6 months following the start of treatment and 1 month after the last ERT administration.
  • a cardiac perfusion with PBS was performed, and the liver, kidney, spleen and heart were collected.
  • Tissue samples were fixed in a methacarn solution (30% chloroform, 60% methanol, 10% acetic acid) for 24 h or frozen in dry ice (for ARSB activity and GAG quantitative assays).
  • Serum ARSB levels were measured by an immune capture assay based on the use of a specific anti-hARSB polyclonal antibody (Covalab, Villeurbanne, France).
  • a specific anti-hARSB polyclonal antibody Covalab, Villeurbanne, France.
  • Ninety-six-well plates (Nunclon, Roskilde, Denmark) were coated with 5 ⁇ g/ml in 0.1 M NaHC03 (100 ⁇ /well) and incubated overnight (O/N) at 4°C. The following day, plates were washed twice with 0.25 M NaCl/0.02 M Tris, pH 7, and then blocked with 1% milk in 0.25 M NaCl/0.02 M Tris, pH 7 (blocking solution), for 2 h at room temperature.
  • Plates were washed again, as described above, and then 50 ⁇ of standard and unknown samples (diluted 1 : 10) were added to each well. Plates were shaken for 1 h at room temperature and then incubated at 4°C O/N. The following day, plates were shaken for 1 h at room temperature and then washed 2x with 0.25 M NaCl/0.02 M Tris, pH 7. In total, 100 ⁇ of 5mM 4-methylumbelliferylsulfate potassium salt (4-MUS, Sigma- Aldrich, Milan, Italy) substrate was added to each well and then incubated at 37°C for 4 h. The reaction was stopped by the addition of 100 ⁇ /well of stop solution (glycine 0.2 M).
  • stop solution glycine 0.2 M
  • Serum ARSB was determined based on a rhARSB (Naglazyme, BioMarin Europe, London, UK) standard curve and expressed as pg/mL. 1 1 V vector genome distribution
  • Genomic DNA was extracted from the livers using the DNeasy Blood and Tissue Extraction kit (Qiagen).
  • Real-time PCR analysis was performed on 100 ng of genomic DNA using a set of primers/probe (Fw 5 '-TCTAGTTGCCAGCCATCTGTTGT-3 ' (SEQ ID NO. 15), Rev 5 '- TGGGAGTGGCACCTTCCA-3 ' (SEQ ID NO. 16), Probe 5 '- TCCCCCGTGCCTTCCTTGACC-3 ' (SEQ ID NO. 17)) specific for the viral genome and Taq- Man universal PCR master mix (Applied Biosystems, Foster City, CA, USA). Amplification was run on a 7300 Real-Time PCR system (Applied Biosystems) with standard cycles. All the reactions were performed in triplicate. Assay for ARSB and GUSB enzymatic activity evaluation in tissues
  • Tissues i.e liver, kidney and spleen, were homogenized in water and protein concentrations were determined with the bicinchoninic acid (BCA) protein assay kit (Pierce Protein Research Products, Thermo Fisher Scientific, Rockford, IL, USA).
  • BCA bicinchoninic acid
  • the ARSB assay was performed, as previously described 67 . Briefly, 30 ⁇ g of protein was incubated with 40 ⁇ 1 of the fluorogenic4- methylumbelliferyl sulfate substrate (12.5mM; Sigma- Aldrich, Saint Louis, MO, USA) for 3 h at 37°C in the presence of 40 ⁇ silver nitrate (0.75mM; Carlo Erba, Milan, Italy), which is known to inhibit the activity of other sulfatases.
  • reaction was stopped by adding 200 ⁇ of carbonate glycine stop buffer and the fluorescence of the 4-methylumbelliferone liberated was measured on a multiplate reader (TEC AN Infinite F200) at 365 nm (excitation) and 460 nm (emission).
  • TEC AN Infinite F200 TEC AN Infinite F200
  • ⁇ -glucuronidase (GUSB) assay was performed, as previously described 68 . Briefly, 200 ⁇ of protein was incubated with 400 ⁇ of GUS assay buffer (50 mM NaP0 4 pH 7, 5mM DTT, ImM EDTA, 0.1% Triton X-100) and 100 ⁇ of the fiuorogenic 4-methylumbelliferyl-P-d- glucuronide (MUG) substrate (5mM; Sigma-Aldrich, Saint Louis, MO, USA) for 30 min at 37°C. The reaction was stopped by adding 900 ⁇ of stop buffer (0.2mM Na 2 C0 3 , pH 9.5) to 50 ⁇ of sample. The fluorescence was measured on a multiplate reader (GloMax-Multi detection system Promega) at 388 nm (excitation) and 480 nm (emission).
  • GUSB ⁇ -glucuronidase
  • Enzyme activities were calculated with a standard curve of the fluorogenic4- methylumbelliferone product (12.5mM; Sigma-Aldrich, Saint Louis, MO, USA). For tissue lysates the activity was expressed as nanomoles per milligram of protein per hour (nmol/mg/h).
  • Urine samples were diluted 1 :50 in water to measure GAG content.
  • GAG concentrations were determined on the basis of a dermatan sulfate standard curve (Sigma-Aldrich, Saint Louis, MO, USA).
  • Tissue GAGs were expressed as micrograms of GAG per milligram of protein ⁇ g GAG/mg protein).
  • Urinary GAGs were normalized to creatinine content which was measured with a creatinine assay kit (Quidel, San Diego, CA, USA).
  • the units of urinary GAGs are micrograms per micromole of creatinine ⁇ g GAG/ ⁇ creatinine).
  • Urinary GAGs were reported as percentage of AF control mice. The urinary GAG levels measured at each time point were averaged for each group.
  • Alcian blue staining in heart valves and myocardium was quantified to provide a measure of GAG storage. Specifically, Alcian blue staining was quantified by measuring RGB intensity on histological section using the Image J software. RGB may assume integer values from 0 to 255. The more intense is the Alcian Blue staining, the lower is the RBG value. Four different areas were randomly selected in each valve. As far as myocardium, five areas corresponding to Alcian blue spots were randomly selected per each section. Where Alcian blue spots were not present, as in NR and some treated mice, five equivalent areas were randomly selected. RGB was measured per each area and then averaged for each animal and each group of animals, as reported in Fig. 4 and 5. GAG levels
  • Urine samples should be diluted between 1 :50 in water. Depending on the assay used, use 50 ul of sample (microplate assay) or 100 ul sample (cuvette assay).
  • tissue lyser Homogenize tissue in the tissue lyser (QIAGEN) in water with LAP (protease inhibitor cocktail tablets) (Roche), Pellet cell debris (14000 rpr, 15-20 min, 4°C), Collect supernatant, Measure protein concentration, Dilute tissue at 5 ug/ul.
  • DMB Reagent (10.7 mg DMB in 55mM formate buffer, pH 3.3); 2M Tris (base);
  • DMB 1,9-Dimethyl-methylene blue
  • Tris base (MW 121,14) ;
  • the DS should be diluted with water to obtain concentrations of 40, 20, 10, 5, 2.5, and 1.25 ug/ml (standard can be stored at -20°C)
  • Serum ARSB The ANOVA p value is 2.00 e "16 ; the p value of NR vs AF is: 4.88e "13 ; the /? value of ERT vs AF is: 1.00; the p value of AAV 2x10 11 vs AF is: 0.99; the p value of AAV 2xlO n + ERT vs AF is: 0.83; the p value of AAV 6xlO n vs AF is: 0.02; the p value of AAV 6xlO n + ERT vs AF is: 6.90e "4 ;
  • Liver genome copies The ANOVA p value is 4.85e “8 ; the p value of AAV 2xlO n vs AAV 6xlO n is: 2.20e “6 ; the p value of AAV 2xlO n + ERT vs AAV 6xlO n + ERT is: 3.70e "6 ; the p value of AAV 2xlO n vs AAV 2xlO n + ERT is: 0.98; the p value of AAV 6xlO n vs AAV 6xlO n + ERT is: 0.99;
  • Liver ARSB activity The ANOVA p value is 3.75e “9 ; the p value of ERT vs AF is: 0.58; the p value of AAV 2xlO n vs AF is: 0.03; the p value of AAV 2xlO n + ERT vs AF is: l .OOe “3 ; the p value of AAV 6x10 11 vs AF is: l .OOe "7 ; the p value of AAV 6x10 n + ERT vs AF is: ⁇ 3.75e "9 ; the p value of AAV 2xlO n vs AAV 6xlO n is: l .OOe "3 ; the p value of AAV 2xlO n + ERT vs AAV 6xlO n + ERT is: 6.00e "3 ; the p value of NR vs AF is 2.17e “8 .
  • Liver GAGs The ANOVA p value is 7.93e “21 ; the p value of NR vs AF is ⁇ 7.93e “21 ; the p value of ERT vs AF is: ⁇ 7.93e “21 ; the p value of AAV 2xlO n vs AF is: ⁇ 7.93e “21 ; the p value of AAV 2xlO n + ERT vs AF is: ⁇ 7.93e "21 ; the p value of AAV 6xlO n vs AF is: ⁇ 7.93e "21 ; the p value of AAV 6xlO n + ERT vs AF is: ⁇ 7.93e "21 ; the p value of ERT vs NR is: 0.99; the p value of AAV 2xlO n vs NR is: 0.99; the p value of AAV 2xlO n + ERT vs NR is: 0.99; the
  • Kidney ARSB activity The ANOVA p value is 1.28e “5 ; the p value of ERT vs AF is: 0.22; the p value of AAV 2xlO n vs AF is: 2.00e “3 ; the p value of AAV 2xlO n + ERT vs AF is: 8.20e “5 ; the p value of AAV 6xlO n vs AF is: 8.30e “5 ; the p value of AAV 6xlO n + ERT vs AF is: l .OOe “ 3 ; the p value of NR vs AF is 1.80e "8 .
  • Kidney GAGs The ANOVA p value is 1.16e “15 ; the p value of NR vs AF is ⁇ 1.16e “15 ; the p value of ERT vs AF is: l .OOe “7 ; the p value of AAV 2xlO n vs AF is: 4.00e “7 ; the p value of AAV 2xlO n + ERT vs AF is: ⁇ 1.16e "15 ; the p value of AAV 6xlO n vs AF is: ⁇ 1.16e "15 ; the p value of AAV 6xlO n + ERT vs AF is: ⁇ 1.16e "15 ; the p value of ERT vs NR is: 0.42; the p value of AAV 2xlO n vs NR is: 0.03; the p value of AAV 2xlO n + ERT vs NR is: 0.99; the p
  • Spleen ARSB activity The ANOVA p value is 5.73e “6 ; the p value of ERT vs AF is: 0.20; the p value of AAV 2xlO n vs AF is: 7.00e “3 ; the p value of AAV 2xlO n + ERT vs AF is: 1.12e “4 ; the p value of AAV 6xlO n vs AF is: 2.46e “4 ; the p value of AAV 6xlO n + ERT vs AF is: 2.46e “ 5 ; the p value of NR vs AF is 4.28e “9 .
  • Spleen GAGs The ANOVA p value is 1.49e 18 ; the p value of NR vs AF is ⁇ 1.49e 18 ; the p value of ERT vs AF is: 1.08e n ; the p value of AAV 2xlO n vs AF is: 1.67e 10 ; the p value of AAV 2xlO n + ERT vs AF is: ⁇ 1.49e 18 ; the p value of AAV 6xlO n vs AF is: ⁇ 1.49e 18 ; the p value of AAV 6xlO n + ERT vs AF is: ⁇ 1.49e "18 ; the p value of ERT vs NR is: 0.66; the p value of AAV 2xlO n vs NR is: 0.04; the p value of AAV 2xlO n + ERT vs NR is: 0.98; the p value of AAV 6xl
  • the ANOVA p value is 6.25e ⁇ 12 ; the p value of NR vs AF is 3.32e ⁇ 7 ; the p value of ERT vs AF is: 1.00; the p value of AAV 2x10 11 vs AF is: 1.00; the p value of AAV 2xlO n + ERT vs AF is: 1.00; the p value of AAV 6xlO n vs AF is: 1.00; the p value of AAV 6xlO n + ERT vs AF is: 1.00; post-natal day 60: the ANOVA p value is 1.09e 14 ; the p value of NR vs AF is: 7.85e 12 ; the p value of ERT vs AF is: 1.00; the p value of AAV 2xlO n vs AF is: 0.99; the p value of AAV 2xlO n + ERT vs
  • the ANOVA p value is ⁇ 2.00 e "16 ; the p value of NR vs AF is ⁇ 2.00e "16 ; the p value of ERT vs AF is: 6.0 le “5 ; the p value of AAV 2xlO n vs AF is: ⁇ 2.00e "16 ; the p value of AAV 2xlO n + ERT vs AF is: ⁇ 2.00e "16 ; the p value of AAV 6xlO n vs AF is: ⁇ 2.00e "16 ; the p value of AAV 6xlO n + ERT vs AF is: ⁇ 2.00e "16 ; the p value of ERT vs NR is: ⁇ 2.00e "16 ; the p value of AAV 2xlO n vs NR is: ⁇ 2.00e "16 ; the p value of AAV 2xlO n + ERT vs
  • Liver ⁇ -glucuronidase activity (a): The ANOVA p value is 8.88e "3 ; the p value of NR vs AF is 0.05; the p value of ERT vs AF is 0.03; the p value of AAV 6xlO n vs AF is 0,03; the p value of AAV 6x10 11 + ERT vs AF is 0.08; the p value of ERT vs NR is 0.99; the p value of AAV 6xlO n vs NR is 0.99; the p value of AAV 6xlO n + ERT vs NR is 0.90.
  • Kidney ⁇ -glucuronidase activity (b): The ANOVA p value is 7.16e “7 ; the p value of NR vs AF is l .OOe “6 ; the p value of ERT vs AF is 2.50e “4 ; the p value of AAV 6xlO n vs AF is 8.99e 5 ; the p value of AAV 6x10 11 + ERT vs AF is 2.30e “6 ; the p value of ERT vs NR is 0.09; the p value of AAV 6xlO n vs NR is 0.21; the p value of AAV 6xlO n + ERT vs NR is 0.99.
  • Example 1 Increased serum ARSB levels in MPS VI transgenic mice treated with combined monthly ERT and gene therapy
  • MPS VI mice received at postnatal day 30 (p30) a single intravenous (i.v) administration of either 2xlO n or 6xlO n gc/kg of AAY2/S. TBG. hARSB, which encodes human ARSB (hARSB) under the control of the liver-specific thyroxine-binding globulin (TBG) promoter, and/or monthly i.v injections of lmg/kg rhARSB (Naglazyme, BioMarin Europe, London, UK), which is the dose currently used in MPS VI patients management (canonical ERT schedule) 6 ' 7 ' 49 ⁇ 52 .
  • i.v intravenous
  • MPS VI mice were either left untreated or received a combination of monthly administrations of ERT and a single injection of the control AAV2/8.TBG.eG vector, which encodes the enhanced green fluorescence protein (eGFP) under the control of the TBG promoter.
  • Serum ARSB was undetectable in affected control (AF) mice (Table 1).
  • AAV adeno-associated viral vector
  • AF affected MPS VI untreated mice
  • ARSB arylsulfatase B
  • GAGs glycosaminoglycans
  • ERT enzyme replacement therapy
  • gc genome copies
  • NR normal untreated mice
  • n.a not applicable. Dashed lines refer to values below the detection limit of the assay.
  • Each serum ARSB value is the mean of all the time points measured in that group over time and is expressed as pg/ml. Measurements in tissues were done at the time of sacrifice (180 or 210 days of age).
  • ARSB activity in tissues is expressed as nmol/mg protein/hour; GAG levels in tissues are expressed as ⁇ g GAG/mg protein; genome copies in livers are expressed as genome copies/molecule of diploid genome.
  • the AAV vector dose used (gc/kg) is reported per each group.
  • the number of animals in the NR group is: 16-24 for serum ARSB [23 at post-natal day 30 (p30) and pi 50, 24 at p60, p90 and pi 20, 22 at pi 80 and 16 at p210];-23 for ARSB activity and GAGs levels in tissues.
  • the number of animals in the AF group is: 9, except for serum ARSB (3-6).
  • Genome copies in liver were analyzed in 3 un-injected (2NR and 1 ERT) mice as control. Values are represented as mean ⁇ SE.
  • Statistical comparisons were made using the one-way ANOVA and the Tukey post hoc test.
  • the p value vs. AF is: * ⁇ 0.05 and ** ⁇ 0.01. The exact p values obtained are indicated in the Material and Methods section.
  • the inventors measured ARSB enzyme activity and AAV vector genome copies (gc) in the livers from treated and control mice at the end of the study, i.e 180 or 210 days of age (Table 1). Persistence of liver transduction was confirmed by the presence of detectable AAV vector gc in mice receiving gene therapy.
  • Example 2 Increased urinary GAG reduction in mice receiving gene therapy in combination with ERT
  • Urinary GAGs were measured monthly in MPS Vl-treated mice as well as in age-matched NR and AF controls, from p60, i.e. one month after the start of treatment. Urinary GAG levels measured at each time point were averaged for each group and the resulting value was reported as a percentage (%) of age-matched AF controls (Fig. 2 and Fig. 3).
  • urinary GAGs decreased more in mice receiving the combined therapy than in those receiving the corresponding single treatments. Indeed, urinary GAGs were significantly lower (61% of AF) in mice treated with both 2xlO n gc/kg of AAV and ERT than in mice treated with either monthly ERT (82% of AF, p value: « 0.01) or 2xlO n gc/kg of AAV (73% of AF, p value: « 0.01).
  • ARSB activity and GAG levels were measured in the liver, kidney, and spleen of MPS VI- treated and control mice (Table 1).
  • ARSB activity was undetectable in tissues of AF controls.
  • MPS VI mice receiving ERT (with or without gene therapy) were sacrificed one month after the last injection of rhARSB to measure the residual tissue enzymatic activity.
  • ERT with or without gene therapy
  • ARSB activity was almost undetectable in the serum of mice treated with ERT alone, the inventors found ARSB activity in tissues up to 1 month after injection (Table 1), although at levels lower than those previously measured in mice receiving weekly ERT 15 .
  • Increased ARSB activity was observed in the liver of all treated mice; detectable activity was variably observed in the spleen and kidney of treated mice, although at levels lower than those measured in the liver (Table 1). Specifically, a statistically significant increase in ARSB activity compared to AF was observed in all treated groups but the one that received monthly ERT.
  • Beta-glucuronidase (GUSB) activity has been found to be secondarily increased in tissues from MPS VI cats as result of ARSB deficiency 53 .
  • GUSB activity was thus evaluated in tissues of MPS VI mice treated with either the combination of 6xlO n gc/kg of AAV and ERT or single therapies, and in NR and AF controls.
  • GUSB activity was significantly increased in liver and kidney but not in spleen of MPS VI mice compared to NR (Figs. 6a,b). While GUSB activity was completely normalized in liver regardless of the treatment, only mice receiving the combined therapy showed normalized levels of GUSB activity in kidney, although none of the groups of treatment was statistically different than NR controls (Figs. 6a,b).
  • the inventors performed Alcian blue staining on heart histological sections from treated and control mice (Fig. 5) and found a marked reduction of GAG levels in the myocardium of MPS VI mice (Fig. 5 and 9), with the exception of those receiving either ERT or 2x10 11 gc/kg of AAV, where only a slight reduction was observed.
  • the Alcian blue staining quantification in heart valves (Fig. 8) and myocardium (Fig.9) shows consistent reduction in mice treated with AAV in combination with ERT, where GAG storage was comparable to either NR controls .
  • the inventors show that therapeutic efficacy can be obtained by combining gene therapy with rarified ERT. In particular, this was demonstrated by a great reduction of both urinary GAGs and storage in myocardium and heart valves observed in mice receiving combined monthly ERT and gene therapy. These levels of correction were similar to normal controls.
  • gene therapy may be regarded as a means to decrease the frequency of ERT infusions. While gene therapy could provide baseline enzyme levels to taper GAG levels, the high intracellular levels of therapeutic enzyme achieved with ERT can be used only occasionally to help clear tissues from any GAGs storage in excess.
  • the use of a rarified ERT schedule should lead to several important advantages, including reduction of both allergic reaction associated with the frequent infusion of recombinant enzyme and the costs of ERT, that range between euro 150,000 and euro 450,000 per patient/year 8 (depending on the patient weight) in the case of MPS VI.
  • the high costs may limit the access to the therapy to patients living in less developed countries and where therapies are not supported by the public health system 4 ' 8 . This scenario may change if a single administration of low dose gene therapy allows ratifying the ERT schedule.
  • liver-directed gene therapy has been demonstrated to either prevent the generation of humoral immunity to the transgene product in several models of LSDs 59 or to eradicate it, if already present 60 ⁇ 62 .
  • immune-mo dulatory gene therapy with a sub-therapeutic dose of vector was shown to enhance the efficacy of ERT in murine Pompe disease by preventing the generation of humoral immunity to recombinant alfa-glucosidase 20 ' 63 . Therefore, gene therapy may also positively impact on ERT therapeutic efficacy and safety by avoiding the generation of inhibitors to therapeutic proteins, which is a limit to the successful treatment of several inherited diseases.
  • this study helps managing patients with LSDs for which ERT is available and who are enrolled in gene therapy clinical trials.
  • the inventors are indeed developing a phase I/II study to test the efficacy of gene therapy for MPS VI (http://meusix.tigem.it). If efficacy is observed that is inferior to that observed during ERT, these patients who have received gene therapy could be put on a rarified rather than on the canonical highly frequent ERT schedule.
  • the inventors show in a mouse model the therapeutic efficacy of a novel combinatorial gene therapy/ERT approach for MPS VI, and potentially other LSDs. By taking advantage of the different pharmacokinetics and dynamics of either approach, this combination has the potential to reduce the risks and costs associated with gene therapy and ERT, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé de traitement de MPS VI comprenant l'administration d'une arylsulfatase B par thérapie génique à un sujet en ayant besoin, ledit sujet recevant l'administration d'un traitement de substitution d'enzyme arylsulfatase B (ERT) moins fréquemment qu'une fois par semaine.
PCT/EP2017/072779 2016-09-09 2017-09-11 Polythérapie pour la mucopolysaccharidose de type vi (syndrome de maroteaux-lamy) Ceased WO2018046737A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP17768071.7A EP3509628A1 (fr) 2016-09-09 2017-09-11 Polythérapie pour la mucopolysaccharidose de type vi (syndrome de maroteaux-lamy)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662385670P 2016-09-09 2016-09-09
US62/385,670 2016-09-09

Publications (1)

Publication Number Publication Date
WO2018046737A1 true WO2018046737A1 (fr) 2018-03-15

Family

ID=59887245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/072779 Ceased WO2018046737A1 (fr) 2016-09-09 2017-09-11 Polythérapie pour la mucopolysaccharidose de type vi (syndrome de maroteaux-lamy)

Country Status (2)

Country Link
EP (1) EP3509628A1 (fr)
WO (1) WO2018046737A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US11952585B2 (en) 2020-01-13 2024-04-09 Homology Medicines, Inc. Methods of treating phenylketonuria
US12076420B2 (en) 2020-05-27 2024-09-03 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
US12203094B2 (en) 2018-02-01 2025-01-21 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal

Non-Patent Citations (102)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences, 19th Ed.", 1995, MACK PUBLISHING CO.
AKIYAMA, K ET AL., MOLECULAR GENETICS AND METABOLISM, vol. 111, 2014, pages 139 - 146
ALESSANDRA TESSITORE ET AL: "Biochemical, Pathological, and Skeletal Improvement of Mucopolysaccharidosis VI After Gene Transfer to Liver but Not to Muscle", MOLECULAR THERAPY, vol. 16, no. 1, January 2008 (2008-01-01), US, pages 30 - 37, XP055421408, ISSN: 1525-0016, DOI: 10.1038/sj.mt.6300325 *
ALLIEGRO ET AL., MOLECUALR THERAPY, 2016
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ANNONI, A ET AL., EMBO MOL MED, vol. 5, 2013, pages 1684 - 1697
AUCLAIR, D ET AL., MOLECULAR GENETICS AND METABOLISM, vol. 78, 2003, pages 163 - 174
BELL, P ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 12, 2005, pages 299 - 306
BERNS: "Virology", 1990, RAVEN PRESS, pages: 1743 - 1764
BIFFI, A, HUM MOL GENET, 2015
BIJARNIA, S ET AL., J PAEDIATR CHILD HEALTH, vol. 45, 2009, pages 469 - 472
BLACKLOWE: "Parvoviruses and Human Disease", 1988, pages: 165 - 174
BRAUNLIN EA ET AL., JOURNAL OF INHERITED METABOLIC DISEASE, vol. 34, 2011, pages 1183 - 1197
BRAUNLIN, EA ET AL., J INHERIT METAB DIS, vol. 34, 2011, pages 1183 - 1197
BROOKS, DA ET AL., BIOCHEM, vol. J307, 1995, pages 457 - 463
BRUNETTI-PIERRI, N; AURICCHIO, A: "The Metabolic and Molecular Bases of Inherited Diseases", 2010, MCGRAW HILL
BYRNE, BJ ET AL., HUMAN GENE THERAPY, vol. 23, 2012, pages 808 - 815
CARTER: "Handbook of Parvoviruses", vol. 1, 1989, pages: 169 - 228
CHANG, PL; ROSA, NE; DAVIDSON, RG, ANAL BIOCHEM, vol. 117, 1981, pages 382 - 389
CHIORINI ET AL., J. VIR., vol. 71, 1997, pages 6823 - 33
CHIORINI ET AL., J. VIR., vol. 73, 1999, pages 1309 - 1319
COTUGNO, G ET AL., HUMAN GENE THERAPY, vol. 21, 2010, pages 555 - 569
COTUGNO, G ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 19, 2011, pages 461 - 469
COTUGNO, G ET AL., PLOS ONE, vol. 7, 2012, pages e33286
CRAWLEY, AC ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 97, 1996, pages 1864 - 1873
CRUDELE, JM ET AL., BLOOD, vol. 125, 2015, pages 1553 - 1561
DALY, TM; VOGLER, C; LEVY, B; HASKINS, ME; SANDS, MS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 96, 1999, pages 2296 - 2300
DE JONG, JG ET AL., CLINICAL CHEMISTRY, vol. 35, 1989, pages 1472 - 1477
DE JONG, JG; WEVERS, RA; LAARAKKERS, C; POORTHUIS, BJ, CLIN CHEM, vol. 35, 1989, pages 1472 - 1477
DESNICK, RJ; SCHUCHMAN, EH, ANNU REV GENOMICS HUM GENET, vol. 13, 2012, pages 307 - 335
DONSANTE, A ET AL., SCIENCE, vol. 317, 2007, pages 477
ELIYAHU, E; WOLFSON, T; GE, Y; JEPSEN, KJ; SCHUCHMAN, EH; SIMONARO, CM, PLOS ONE, vol. 6, 2011, pages e22447
EVERS, M ET AL., PNAS, vol. 93, 1996, pages 8214 - 8219
FENG; DOOLITTLE, J. MOL. EVOL., vol. 35, 1987, pages 351 - 360
FERLA, R ET AL., HUMAN GENE THERAPY, vol. 24, 2013, pages 163 - 169
FERLA, R ET AL., HUMAN GENE THERAPY, vol. 25, 2014, pages 609 - 618
GABRIELLA COTUGNO ET AL: "Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer", MOLECULAR THERAPY, vol. 19, no. 3, March 2011 (2011-03-01), US, pages 461 - 469, XP055421410, ISSN: 1525-0016, DOI: 10.1038/mt.2010.257 *
GIUGLIANI ROBERTO ET AL: "Therapy for mucopolysaccharidosis VI: (Maroteaux-Lamy syndrome) present status and prospects", PEDIATRIC ENDOCRINOLOGY REVIEWS, vol. 12, no. Suppl 1, 31 August 2014 (2014-08-31), pages 152 - 158, XP009501143, ISSN: 1565-4753, Retrieved from the Internet <URL:https://www.pediatricendoreviews.com/vulume-12-supp-1> *
GIUGLIANI, R ET AL., AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2014
HANDLER, RJ ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 125, 2015, pages 870 - 880
HARMATZ, P ET AL., ACTA PAEDIATR SUPPL, vol. 94, 2005, pages 61 - 68
HARMATZ, P ET AL., MOLECULAR GENETICS AND METABOLISM, vol. 94, 2008, pages 469 - 475
HARMATZ, P ET AL., PEDIATRICS, vol. 115, 2005, pages e681 - 689
HARMATZ, P ET AL., THE JOURNAL OF PEDIATRICS, vol. 144, 2004, pages 574 - 580
HARMATZ, P ET AL., THE JOURNAL OF PEDIATRICS, vol. 148, 2006, pages 533 - 539
HARTUNG, SD ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 9, 2004, pages 866 - 875
HAWKINS-SALSBURY, JA ET AL., JNEUROSCI, vol. 35, 2015, pages 6495 - 6505
HAWKINS-SALSBURY, JA; REDDY, AS; SANDS, MS, HUM MOL GENET, vol. 20, 2011, pages R54 - 60
HELDERMON, CD ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 18, 2010, pages 873 - 880
HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1989, pages 10915
HIGGINS; SHARP, CABIOS, vol. 5, 1989, pages 151 - 153
J. A. HAWKINS-SALSBURY ET AL: "Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?", HUMAN MOLECULAR GENETICS, vol. 20, no. R1, 15 April 2011 (2011-04-15), pages R54 - R60, XP055080994, ISSN: 0964-6906, DOI: 10.1093/hmg/ddr112 *
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787
LI, H ET AL., BLOOD, vol. 117, 2011, pages 3311 - 3319
LIN, D ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 15, 2007, pages 44 - 52
LODUCA, PA; HOFFMAN, BE; HERZOG, RW, CURR GENE THER, vol. 9, 2009, pages 104 - 114
MACAULEY, SL ET AL., ANNALS OF NEUROLOGY, vol. 71, 2012, pages 797 - 804
MACAULEY, SL ET AL., JNEUROSCI, vol. 34, 2014, pages 13077 - 13082
MARIALUISA ALLIEGRO ET AL: "Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease", MOLECULAR THERAPY, vol. 24, no. 12, 25 October 2016 (2016-10-25), US, pages 2054 - 2063, XP055421414, ISSN: 1525-0016, DOI: 10.1038/mt.2016.181 *
MARKUSIC, DM ET AL., EMBO MOL MED, vol. 5, 2013, pages 1698 - 1709
MINGOZZI, F; HIGH, KA, NAT REV GENET, vol. 12, 2011, pages 341 - 355
NATHWANI, AC ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, 2011, pages 2357 - 2365
NATHWANI, AC ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 371, 2014, pages 1994 - 2004
NATHWANI, AC; ROSALES, C; MCINTOSH, J; RASTEGARLARI, G; NATHWANI, D; RAJ, D ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 19, 2011, pages 876 - 885
NAULT, JC ET AL., NATURE GENETICS, vol. 47, 2015, pages 1187 - 1193
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
NEUFELD, EF: "Lysosomal storage diseases", ANNU REV BIOCHEM, vol. 60, 1991, pages 257 - 280
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444
PONDER, KP ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 20, 2012, pages 898 - 907
PORTO, C ET AL., J INHERIT METAB DIS, vol. 35, 2012, pages 513 - 520
PORTO, C ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 17, 2009, pages 964 - 971
REDDY, AS ET AL., JNEUROSCI, vol. 31, 2011, pages 9945 - 9957
RITA FERLA ET AL: "Combination of low - dose gene therapy and monthly enzyme replacement therapy improves the phenotype of a mouse model of lysosomal storage disease.", MOLECULAR THERAPY, vol. 23, no. SUPPL: 1, May 2015 (2015-05-01), pages S112, XP055421443 *
RITA FERLA ET AL: "Similar Therapeutic Efficacy Between a Single Administration of Gene Therapy and Multiple Administrations of Recombinant Enzyme in a Mouse Model of Lysosomal Storage Disease", HUMAN GENE THERAPY, vol. 25, no. 7, July 2014 (2014-07-01), US, pages 609 - 618, XP055421419, ISSN: 1043-0342, DOI: 10.1089/hum.2013.213 *
ROSE: "Comprehensive Virology", vol. 3, 1974, pages: 1 - 61
RUTLEDGE ET AL., J. VIR., vol. 72, 1998, pages 309 - 319
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SANDS, MS ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 99, 1997, pages 1596 - 1605
SANDS, MS; DAVIDSON, BL, MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 13, 2006, pages 839 - 849
SCHLANDER, M; BECK, M, CURR MED RES OPIN, vol. 25, 2009, pages 1285 - 1293
SCRIVER ET AL.,: "The Metabolic Basis of Inherited Disease", 1989, MCGRAW-HILL, article NEUFELD ET AL.: "The mucopolysaccharidoses", pages: 1565 - 1587
SCRIVER, R.: "The Online Metabolic and Molecular Bases of Inherited Disease", 2010, MCGRAW HILL, article NEUFELD, E; MUENZER, J: "The mucopolysaccharidoses", pages: 1 - 73
SHANNON L MACAULEY: "Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem", PEDIATRIC ENDOCRINOLOGY REVIEWS, vol. 13 Suppl 1, June 2016 (2016-06-01), IL, pages 639 - 648, XP055421382, ISSN: 1565-4753 *
SILLENCE, D; WATERS, K; DONALDSON, S; SHAW, PJ; ELLAWAY, C, JIMD REPORTS, vol. 2, 2012, pages 103 - 106
SKORUPA, AF ET AL., EXP NEUROL, vol. 160, 1999, pages 17 - 27
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
SORRENTINO, NC ET AL., EMBO MOL MED, vol. 5, 2013, pages 675 - 690
SPAMPANATO, C ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 19, 2011, pages 860 - 869
SRIVASTAVA ET AL., J. VIR., vol. 45, 1983, pages 555 - 64
STRAUCH, OF ET AL., PEDIATR RES, vol. 54, 2003, pages 701 - 708
SUN, B ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 11, 2005, pages 57 - 65
SUN, B ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 18, 2010, pages 353 - 360
TESSITORE, A ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 16, 2008, pages 30 - 37
THOMPSON ET AL., NUCLEIC ACIDS RESEARCH, vol. 22, 1994, pages 4673 - 4680
WANG, L ET AL., HUMAN GENE THERAPY, vol. 23, 2012, pages 533 - 539
WICKES, BL; EDMAN, JC, MOL MICROBIOL, vol. 16, 1995, pages 1099 - 1109
WOLF, DA ET AL., NEUROBIOL DIS, vol. 43, 2011, pages 123 - 133
WU ET AL., J. VIR., vol. 74, 2000, pages 8635 - 47
WYATT, K ET AL., HEALTH TECHNOL ASSESS, vol. 16, 2012, pages 1 - 543
YAN ET AL., J. VIROL., vol. 79, no. 1, 2005, pages 364 - 379
ZAMBROWICZ, BP ET AL., PNAS, vol. 94, 1997, pages 3789 - 3794
ZIEGLER, RJ ET AL., MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 15, 2007, pages 492 - 500

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US11951183B2 (en) 2018-02-01 2024-04-09 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US12064486B2 (en) 2018-02-01 2024-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US12203094B2 (en) 2018-02-01 2025-01-21 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
US11952585B2 (en) 2020-01-13 2024-04-09 Homology Medicines, Inc. Methods of treating phenylketonuria
US12076420B2 (en) 2020-05-27 2024-09-03 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof

Also Published As

Publication number Publication date
EP3509628A1 (fr) 2019-07-17

Similar Documents

Publication Publication Date Title
TWI827560B (zh) 用於製備病毒載體之手段及方法與其用途
US20240009327A1 (en) Gene therapy for mucopolysaccharidosis iiib
EP3519569B1 (fr) Vecteurs viraux recombinés adéno-associés pour le traitement de la mucopolysaccharidose
JP2022515338A (ja) 遺伝子送達のための組み換えアデノ随伴ウイルスベクター
US20230279430A1 (en) Gene therapy for mucopolysaccharidosis iiia
HUE035779T2 (en) Gene therapy for lysosomal storage disorders
US20230365955A1 (en) Compositions and methods for treatment of fabry disease
WO2018046737A1 (fr) Polythérapie pour la mucopolysaccharidose de type vi (syndrome de maroteaux-lamy)
JP2018501791A (ja) 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用
US20250179522A1 (en) Human pah expression cassette for treatment of pku by liver-directed gene replacement therapy
US20190343929A1 (en) Combined therapy for mucopolysaccharidosis type vi (maroteaux-lamy-syndrome)
US20250161493A1 (en) Compositions and methods for in vivo nuclease-mediated treatment of ornithine transcarbamylase (otc) deficiency
US20240408157A1 (en) Compositions and methods for treatment of fabry disease
RU2848343C1 (ru) Кассета экспрессии pah человека для лечения pku с помощью направленной на печень генной заместительной терапии
US20230175014A1 (en) Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
KR20250156211A (ko) 글루코실세라미다제 베타 1 결핍증과 관련된 신경 장애의 치료를 위한 조성물 및 방법
HK40012896A (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
HK40012896B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17768071

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017768071

Country of ref document: EP

Effective date: 20190409